Evommune initiates Phase 2b trial of EVO756 for migraine, top-line data expected in 2027

Evommune initiated dosing in a global Phase 2b trial of EVO756 for migraine prophylaxis; top-line data expected in 2027.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Jul. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important informati…

Evommune initiated dosing in a global Phase 2b trial of EVO756 for migraine prophylaxis; top-line data expected in 2027.

Key Highlights:

First patient dosed in Phase 2b randomized, double-blind, placebo-controlled trial of oral MRGPRX2 antagonist EVO756.
About 330 adults with refractory migraine (≥6 migraine days/mo) to be randomized across two doses and placebo for 12 weeks.
Trial explores daily doses up to 100 mg and targets mean change from baseline in monthly migraine days as primary endpoint.
EVO756 designed to inhibit PACAP, VIP and Substance P via MRGPRX2 in trigeminal neurons and meningeal mast cells.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.